当前位置: X-MOL 学术Cytom. Part A › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Single Cell Phenotypic Profiling of 27 DLBCL Cases Reveals Marked Intertumoral and Intratumoral Heterogeneity.
Cytometry Part A ( IF 2.5 ) Pub Date : 2019-10-22 , DOI: 10.1002/cyto.a.23919
Michael D Nissen 1 , Manabu Kusakabe 1 , Xuehai Wang 1 , Guillermo Simkin 1 , Deanne Gracias 1 , Kateryna Tyshchenko 1 , Ainsleigh Hill 1 , Justin Meskas 1 , Stacy Hung 2 , Elizabeth A Chavez 2 , Daisuke Ennishi 2 , Tomohiro Aoki 2 , Clementine Sarkozy 2 , Joseph M Connors 2 , Pedro Farinha 3 , Graham W Slack 3 , Randy D Gascoyne 2, 3 , Ryan R Brinkman 1 , David W Scott 2 , Christian Steidl 2 , Andrew P Weng 1, 3
Affiliation  

Diffuse large B‐cell lymphoma (DLBCL) is the most common histologic subtype of non‐Hodgkin lymphoma and is notorious for its clinical heterogeneity. Patient outcomes can be predicted by cell‐of‐origin (COO) classification, demonstrating that the underlying transcriptional signature of malignant B‐cells informs biological behavior in the context of standard combination chemotherapy regimens. In the current study, we used mass cytometry (CyTOF) to examine tumor phenotypes at the protein level with single cell resolution in a collection of 27 diagnostic DLBCL biopsy specimens from treatment naïve patients. We found that malignant B‐cells from each patient occupied unique regions in 37‐dimensional phenotypic space with no apparent clustering of samples into discrete subtypes. Interestingly, variable MHC class II expression was found to be the greatest contributor to phenotypic diversity. Within individual tumors, a subset of cases showed multiple phenotypic subpopulations, and in one case, we were able to demonstrate direct correspondence between protein‐level phenotypic subsets and DNA mutation‐defined subclones. In summary, CyTOF analysis can resolve both intertumoral and intratumoral heterogeneity among primary samples and reveals that each case of DLBCL is unique and may be comprised of multiple, genetically distinct subclones. © 2019 International Society for Advancement of Cytometry

中文翻译:

27 例 DLBCL 病例的单细胞表型分析揭示了明显的瘤间和瘤内异质性。

弥漫性大 B 细胞淋巴瘤 (DLBCL) 是非霍奇金淋巴瘤最常见的组织学亚型,因其临床异质性而臭名昭著。患者的预后可以通过细胞来源 (COO) 分类来预测,这表明恶性 B 细胞的潜在转录特征在标准联合化疗方案的背景下会影响生物学行为。在当前的研究中,我们使用质谱流式细胞术 (CyTOF) 在来自未接受治疗的患者的 27 个诊断性 DLBCL 活检标本的集合中以单细胞分辨率在蛋白质水平检查肿瘤表型。我们发现来自每个患者的恶性 B 细胞在 37 维表型空间中占据独特的区域,没有明显的样本聚集成离散的亚型。有趣的是,发现可变 MHC II 类表达是表型多样性的最大贡献者。在单个肿瘤中,一部分病例显示出多个表型亚群,在一个病例中,我们能够证明蛋白质水平的表型亚群与 DNA 突变定义的亚克隆之间存在直接对应关系。总之,CyTOF 分析可以解决原始样本之间的肿瘤间和肿瘤内异质性,并揭示每个 DLBCL 病例都是独一无二的,可能由多个基因不同的亚克隆组成。© 2019 国际细胞计量学促进会 我们能够证明蛋白质水平的表型子集和 DNA 突变定义的亚克隆之间的直接对应关系。总之,CyTOF 分析可以解决原始样本之间的肿瘤间和肿瘤内异质性,并揭示每个 DLBCL 病例都是独一无二的,可能由多个基因不同的亚克隆组成。© 2019 国际细胞计量学促进会 我们能够证明蛋白质水平的表型子集和 DNA 突变定义的亚克隆之间的直接对应关系。总之,CyTOF 分析可以解决原始样本之间的肿瘤间和肿瘤内异质性,并揭示每个 DLBCL 病例都是独一无二的,可能由多个基因不同的亚克隆组成。© 2019 国际细胞计量学促进会
更新日期:2019-10-22
down
wechat
bug